九安医疗(002432) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥190,031,367.60, representing a year-on-year increase of 34.21%[3] - Net profit attributable to shareholders was -¥29,887,791.67, a decrease of 96.44% compared to the same period last year[3] - Basic earnings per share were -¥0.0691, a decrease of 72.75% year-on-year[3] - The company expects a net profit of negative ¥60,000,000 for the year 2019, a significant decline compared to a profit of ¥12,686,800 in 2018[13] - The company reported a net loss of CNY 289,009,262.68, compared to a loss of CNY 209,398,688.61 in the previous year[21] - The net profit for the current period was a loss of ¥45,159,784.73, compared to a loss of ¥22,511,332.49 in the previous period, indicating a significant increase in losses[38] - The net loss attributable to the parent company for the year-to-date period was CNY 79,610,574.07, compared to a loss of CNY 60,979,189.80 in the previous year[33] - The total comprehensive income for the year-to-date period was a loss of CNY 90,985,882.99, compared to a loss of CNY 77,995,790.26 in the previous year[33] Cash Flow - The net cash flow from operating activities was -¥37,210,780.37, an improvement of 55.75% compared to the previous period[3] - Cash flow from operating activities increased to ¥571,903,974.47 from ¥508,763,168.57, representing a growth of approximately 12.4%[39] - The net cash flow from operating activities for the year-to-date was 17,832,833.52 CNY, a significant recovery from -166,633,294.15 CNY in the same period last year[42] - The net cash flow from investment activities was 12,695,792.03 CNY, recovering from a negative cash flow of -245,449,336.61 CNY in the previous year[40] - The net cash flow from financing activities was -68,855,039.90 CNY, compared to -11,406,529.24 CNY in the same period last year[41] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,829,567,467.65, a decrease of 4.12% compared to the end of the previous year[3] - Total assets decreased from CNY 1,908,226,379.51 to CNY 1,829,567,467.65, a decline of approximately 4.1%[19] - Non-current assets totaled CNY 969,035,585.43, down from CNY 1,016,498,314.82, representing a decrease of about 4.7%[19] - Current liabilities decreased significantly from CNY 303,741,212.44 to CNY 158,255,010.17, a reduction of approximately 48%[20] - Long-term borrowings increased from CNY 72,509,052.00 to CNY 197,248,918.20, an increase of about 172.5%[20] - The company's total equity decreased from CNY 1,526,315,911.92 to CNY 1,468,396,614.77, a decline of approximately 3.8%[21] - Total liabilities decreased to CNY 60,337,964.24 from CNY 201,718,285.12, indicating a significant reduction in financial obligations[25] Shareholder Information - The company reported a total of 64,631 shareholders at the end of the reporting period[6] - The top ten shareholders held a combined 33.43% of the shares, with the largest shareholder owning 144,693,102 shares[6] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[7] Expenses - Sales expenses rose by 39.73% to ¥81,833,513.96, primarily due to increased sales costs in European markets[10] - Research and development expenses for Q3 2019 were CNY 15,676,701.85, a decrease of 31.8% from CNY 22,985,235.48 in the previous year[26] - Research and development expenses for the year-to-date period were CNY 51,878,331.63, down from CNY 67,788,586.51, indicating a reduction of 23.5%[32] Tax and Refunds - The company received tax refunds of ¥27,367,177.36, a decrease of 48.75% compared to the previous period[10] - The company received tax refunds amounting to ¥27,367,177.36, down from ¥53,401,424.64 in the previous period, indicating a decrease of approximately 48.7%[39] Other Financial Metrics - The weighted average return on net assets was -2.00%, a decrease of 0.94% compared to the previous year[3] - The company reported a financial expense of CNY -1,611,933.98, compared to CNY -333,194.09 in the previous year, showing a significant decrease in financial costs[32] - The company recorded a significant investment loss of ¥18,562,994.63, compared to a loss of ¥4,731,440.88 in the previous period, indicating a deterioration in investment performance[37] Comprehensive Income - Other comprehensive income after tax for Q3 2019 was CNY 41,052,899.63, compared to a loss of CNY 13,551,272.65 in the previous year[27] - The company reported other comprehensive income after tax of CNY 33,066,585.84, compared to a loss of CNY -8,350,867.55 in the previous year[33] General Observations - The report for the third quarter was not audited, which may affect the reliability of the financial data presented[52] - The company has not disclosed any new product developments or technological advancements in this report[51] - There is no mention of market expansion or acquisition strategies in the current financial report[51] - The company has not provided future outlook or performance guidance in this quarter's report[51]